IMPACT
OmiX Labs has completed two validation studies of eziAMP platform and assay:
- 100 clinical samples (50 positive and 50 negative) in collaboration with St. John’s Hospital, Bangalore. The preliminary sensitivity and specificity was found to be 98% and 100% respectively.
- 127 clinical samples in collaboration with Central TB Division. The sensitivity and specificity was found to be 88.2% and 94.5% respectively
As the next step, eziAMP platform and assay kit will undergo multi-centric clinical validation for TB detection. Similar clinical validation will be conducted for detection of Influenza in collaboration with Manipal Institute of Virology. In addition, Central TB Division, Ministry of Health & Family Welfare, Government of India has price 1000 -1500 INR for 3 diseases), making vast scale adoption more feasible. With higher specificity, better throughput & ease of use, the platform overcomes the limitations of current molecular diagnostics and could be made available to patients in areas with low testing load. offered support for pilot testing of the device at selected sites of the national TB elimination program. The results of pilot study & feasibility study will enable the adoption of eziAMP devices for decentralized detection of TB at primary healthcare level.
“Poor healthcare outcomes are directly correlated with socio-economic status, and it begins with lack of access to accurate and early diagnosis Imagine being sick and the nearest laboratory is 50 kms away or the cost of a test is equal to a week’s wages.The COVID-19 pandemic was yet another reminder where access to RT-PCR diagnostic laboratories in smaller towns and cities in India lagged well behind the metros. OmiX’s journey is to revolutionize diagnostics to enable access to accurate and affordable molecular diagnostics not just for COVID-19, but also other debilitating infections such as Tuberculosis and Influenza.”
Dr. Sudeshna Adak, Co-founder & CEO, OmiX Laboratories Pvt. Ltd.